NasdaqGS:KNSABiotechs
How Investors May Respond To Kiniksa Pharmaceuticals (KNSA) Profit Surge and Upward Revenue Guidance
Kiniksa Pharmaceuticals International recently announced its second quarter and first half 2025 results, reporting a sharp increase in revenue to US$156.8 million for the quarter and a turnaround to net income of US$17.83 million, alongside a new annual revenue forecast of US$625 million to US$640 million.
This marked improvement in profitability and upwardly revised revenue guidance reflects management's increased confidence in demand trends and the company's operational execution in the...